Covalon Q3 revenue rises to CAD 10.04 million as company cites higher-margin US vascular access, surgical consumables mix

• For the three months ended June 30, 2026, revenue rose to CAD 10.04 million from CAD 8.37 million, driven by U.S. vascular growth.
• Gross margin widened to 67% from 46%, reflecting a richer product and geographic mix in higher-margin U.S. consumables.
• Margin also benefited from the absence of a significant inventory write-down recorded in the prior-year quarter.
• Operating expenses were little changed at CAD 4.02 million, as cost controls offset higher R&D and administrative spending.
• Net income jumped to CAD 2.81 million from CAD 64,567, supported by higher gross profit and modest expense growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Covalon Technologies Ltd. published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.